title: Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.
authors.affiliation: Medical University of South Carolina, Hollings Cancer Center, 86 Jonathan Lucas Street, Charleston, SC 29425, United States.
authors.forename: Whitney S
authors.initials: WS
authors.lastname: Graybill
authors.affiliation: Department of Obstetrics and Gynecology, NYU Langone Medical Center, 240 East 38th Street, 19th Floor, New York, NY 10016, United States.
authors.forename: Bhavana
authors.initials: B
authors.lastname: Pothuri
authors.affiliation: Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital, 2222 E. Highland Avenue, Suite 400, Phoenix, AZ 85016, United States.
authors.forename: Dana M
authors.initials: DM
authors.lastname: Chase
authors.affiliation: Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital, 2222 E. Highland Avenue, Suite 400, Phoenix, AZ 85016, United States. Electronic address: Bradley.monk@usoncology.com.
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Monk
mesh_terms: D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use*
chemical_list: D000067856:Poly(ADP-ribose) Polymerase Inhibitors
keywords: Maintenance; Ovarian cancer; PARP inhibitor; Treatment